scholarly journals Short-Term Side Effects after Radioiodine Treatment in Patients with Differentiated Thyroid Cancer

2016 ◽  
Vol 2016 ◽  
pp. 1-5 ◽  
Author(s):  
Liyan Lu ◽  
Fengling Shan ◽  
Wenbin Li ◽  
Hankui Lu
Keyword(s):  
Thyroid Cancer ◽  
Side Effects ◽  
Adverse Effects ◽  
Differentiated Thyroid Cancer ◽  
Gastrointestinal Symptoms ◽  
Medical Intervention ◽  
Short Term ◽  
Remnant Ablation ◽  
Body Sensation ◽  
Node Metastases

Objectives. I-131 therapy for differentiated thyroid cancer (DTC) could induce adverse effects. The purpose of this study was to report and analyze symptoms after I-131 treatment within the hospitalization and present relevant medical intervention.Methods. I-131 doses ranging from 3.7 to 9.25 GBq (100–250 mCi) were administrated for thyroid remnant ablation or treating DTC metastases. 117 patients with DTC for I-131 therapy were monitored through the video and intercommunicating with standardized questionnaire at different time points after I-131 oral administration. Adverse effects were recorded and relevant clinical factors were analyzed.Results. Among all the 117 patients, 55 cases complained of neck’s pain or swelling and 79 cases presented with gastrointestinal symptoms. Pain or swelling of salivary gland occurred in 15 patients, headache and vertigo in 10, insomnia in 9, vocal cord paralysis in 6, fatigue or general malaise in 6, and foreign body sensation in 5. Body numbness and urinary symptoms were observed in only 1 case, respectively. Those side effects were related with sex, pre-I-131 treatment TSH levels, frequency of I-131 therapy, and lymph node metastases.Conclusions. Short-term side effects after I-131 therapy for DTC patients varied individually; severe symptoms were not uncommon but generally did not need emergent medical intervention.

scholarly journals The Association Between The Interval of Radioiodine Treatment and The Response and Adverse Effect in Patients with Non-Progressive Lung Metastases From Differentiated Thyroid Cancer

2021 ◽  
Author(s):  
Hongxi Wang ◽  
Rong Tian ◽  
Lei Shi ◽  
Rui Huang ◽  
Bin Liu
Keyword(s):  
Thyroid Cancer ◽  
Adverse Effects ◽  
Differentiated Thyroid Cancer ◽  
Lung Metastases ◽  
Radioiodine Treatment ◽  
Short Term ◽  
Change Rate ◽  
Response Interval ◽  
Significant Difference ◽  
Term Response

Abstract Purpose To assess the association between the interval of radioiodine treatment (RT) and short-term response and adverse effects in patients with non-progressive lung metastases from differentiated thyroid cancer (DTC).Methods A total of 147 neighboring RT course pairs from 78 patients with 131I-avid non-progressive lung metastases from DTC were retrospectively analyzed. The courses were categorized into two groups by interval of neighboring therapeutic 131-I administrations (≤12 months and >12 months). The short-term therapy response and adverse effects of the two groups were evaluated.Results No significant differences were found between the two groups in the change rate of thyroid stimulating hormone (TSH) stimulated serum thyroglobulin (ΔsTg%) (P=0.806) or the change rate of metastasis lesion long diameter (ΔLLD%) (P=0.246). In the subanalysis considering the number of treatments (3 and >3 times), no significant difference was found (P>0.05). No difference was found in biochemical response (interval ≤12m: P=0.325, interval >12m:P=0.456) or structural response (interval ≤12m: P=0.760, interval >12m: P=0.563) between the former and latter courses with regard to different intervals. No difference was found in adverse events between former and latter courses with regard to different intervals (P>0.05).Conclusions The interval of RTs is not associated with the short-term response or adverse effects in patients with non-progressive lung metastases from DTC. Appropriately prolonging the interval in specific patients seems to be feasible, and the interval of RT should be individually managed in clinical practice.

Short-Term Outcomes after Unilateral versus Complete Thyroidectomy for Malignancy: A National Perspective

2009 ◽  
Vol 75 (1) ◽  
pp. 20-24 ◽  
Author(s):  
Marc Zerey ◽  
Ajita S. Prabhu ◽  
William L. Newcomb ◽  
Amy E. Lincourt ◽  
Kent W. Kercher ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Length Of Stay ◽  
Differentiated Thyroid Cancer ◽  
Operative Management ◽  
National Inpatient Sample ◽  
Short Term ◽  
Thyroid Lobectomy ◽  
Well Differentiated ◽  
National Perspective ◽  
Total Charges

The extent of thyroidectomy for well-differentiated thyroid cancer (WDTC) remains controversial. We compared outcomes of patients undergoing unilateral thyroid lobectomy (UTL) versus complete thyroidectomy (CT) to determine the best operative management of WDTC. We compared outcomes of patients who underwent UTL or CT for malignancy using the 1999 to 2003 editions of the National Inpatient Sample database. A total of 13,854 patients underwent UTL (n = 4,238) and CT (n = 9,616). The CT group was more likely to have complications than the UTL group (15% vs 6%, P < 0.0001). Mean total charges were higher in the CT group ($11,432) versus the UTL group ($9,739), as was LOS (2 days versus 1 day); P < 0.0001. Complete thyroidectomy is associated with increased morbidity, total charges, and length of stay. The higher risk of short-term complications should be considered when considering performing a complete thyroidectomy for WDTC.

Lowest effective 131I activity for thyroid remnant ablation of differentiated thyroid cancer patients

2015 ◽  
Vol 54 (03) ◽  
pp. 137-143 ◽  
Author(s):  
A.-S. Moldovan ◽  
M. Ruhlmann ◽  
R. Görges ◽  
A. Bockisch ◽  
S. Rosenbaum-Krumme ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Cancer Patients ◽  
Differentiated Thyroid Cancer ◽  
Absorbed Dose ◽  
Thyroid Remnant ◽  
Remnant Ablation ◽  
Dose Threshold ◽  
131I Activity ◽  
Pet Ct ◽  
Absorbed Radiation Dose

SummaryAim: A theoretical dosimetry-based model was applied to estimate the lowest effective radioiodine activity for thyroid remnant ablation of low-risk differentiated thyroid cancer patients. Patients, methods: The model is based on the distribution of the absorbed (radiation) dose per administered radioiodine activity and the absorbed dose threshold of 300 Gy for thyroid remnants, the level believed to destroy most thyroid remnants. For this purpose, 124I PET/CT images of 49 thyroid-ectomised patients were retrospectively analysed to measure the distribution of the (average) absorbed doses to thyroid remnant per administered 131I activity. The fraction of thyroid remnants that received at least 300 Gy was determined for standard activities between 0.37 and 5.55 GBq. The lower activity was considered to be equally effective to that obtained with higher activity if the (absolute) fraction difference was below 5%. Results: A total of 62 thyroid remnants were included. The medians and ranges (in parentheses) for the absorbed dose per unit 131I activity were 359 Gy/GBq (34 to 1825 Gy/ GBq). The fractions of thyroid remnants receiving more than 300 Gy at different therapy activities (within parentheses) were 60% (1.11 GBq), 76% (1.85 GBq), 79% (2.22 GBq), and 81–82% for activities between 2.59 and 3.70 GBq. The therapy activity of 1.11 GBq is considerably less effective than that of 1.85 or 2.22 GBq; therapy activities were equally effective in the range between 2.22 to 3.70 GBq. Conclusion: On the basis of the model and the patients' data included, the lowest effective therapy activity appears to be approximately 2.2 GBq to ablate thyroid remnants. The results of this study may help to guide the design of prospective clinical studies.

Thyroid remnant ablation in differentiated thyroid cancer

2015 ◽  
Vol 36 (11) ◽  
pp. 1100-1106 ◽  
Author(s):  
Alfredo Campennì ◽  
Luca Giovanella ◽  
Salvatore A. Pignata ◽  
Maria A. Violi ◽  
Massimiliano Siracusa ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Differentiated Thyroid Cancer ◽  
Thyroid Remnant ◽  
Remnant Ablation

scholarly journals Efficacy of Dosimetric Versus Empiric Prescribed Activity of 131I for Therapy of Differentiated Thyroid Cancer

2011 ◽  
Vol 96 (10) ◽  
pp. 3217-3225 ◽  
Author(s):  
Joanna Klubo-Gwiezdzinska ◽  
Douglas Van Nostrand ◽  
Frank Atkins ◽  
Kenneth Burman ◽  
Jacqueline Jonklaas ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Side Effects ◽  
High Risk ◽  
Confidence Interval ◽  
Odds Ratio ◽  
Differentiated Thyroid Cancer ◽  
Progression Free Survival ◽  
Response To Treatment ◽  
High Risk Patients ◽  
Risk Patients

Abstract Background: The optimal management of high-risk patients with differentiated thyroid cancer (DTC) consists of thyroidectomy followed by radioiodine (131I) therapy. The prescribed activity of 131I can be determined using two approaches: 1) empiric prescribed activity of 131I (E-Rx); and 2) dosimetry-based prescribed activity of 131I (D-Rx). Aim: The aim of the study was to compare the relative treatment efficacy and side effects of D-Rx vs. E-Rx. Methods: A retrospective analysis was performed of patients with distant metastases and/or locoregionally advanced radioiodine-avid DTC who were treated with either D-Rx or E-Rx. Response to treatment was based on RECIST (Response Evaluation Criteria in Solid Tumors) 1.1 criteria. Results: The study group consisted of 87 patients followed for 51 ± 35 months, of whom 43 were treated with D-Rx and 44 with E-Rx. Multivariate analysis, controlling for age, gender, and status of metastases revealed that the D-Rx group tended to be 70% less likely to progress (odds ratio, 0.29; 95% confidence interval, 0.087–1.02; P = 0.052) and more likely to obtain complete response (CR) compared to the E-Rx group (odds ratio, 8.2; 95% confidence interval, 1.2–53.5; P = 0.029). There was an association in the D-Rx group between the observed CR and percentage of maximum tolerable activity given as a first treatment of 131I (P = 0.030). The advantage of D-Rx was specifically apparent in the locoregionally advanced group because CR was significantly higher in D-Rx vs. E-Rx in this group of patients (35.7 vs. 3.3%; P = 0.009). The rates of partial response, stable disease, and progression-free survival, as well as the frequency of side effects, were not significantly different between the two groups. Conclusion: Higher efficacy of D-Rx with a similar safety profile compared to E-Rx supports the rationale for employing individually prescribed activity in high-risk patients with DTC.

scholarly journals TSH Variability of Patients Affected by Differentiated Thyroid Cancer Treated with Levothyroxine Liquid Solution or Tablet Form

2017 ◽  
Vol 2017 ◽  
pp. 1-5 ◽  
Author(s):  
Carlo Cappelli ◽  
Ilenia Pirola ◽  
Elena Gandossi ◽  
Claudio Casella ◽  
Davide Lombardi ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Differentiated Thyroid Cancer ◽  
Liquid Solution ◽  
American Thyroid Association ◽  
Liquid Formulation ◽  
Remnant Ablation ◽  
Tablet Form ◽  
Risk Patients ◽  
Receive Treatment ◽  
To Receive

Background. Recent guidelines from the American Thyroid Association (ATA) indicate that, in many patients affected by differentiated thyroid cancer (DTC), the serum TSH should be maintained between 0.1 and 0.5 mU/L. The purpose of this study was to evaluate the TSH variability of patients affected by DTC treated with liquid L-T4 formulation or in tablet form. Patients and Methods. Patients were eligible if (a) they were submitted to a total thyroidectomy and 131I remnant ablation for DTC in our institution and (b) they were classified low-risk patients according to ATA guidelines 2009. Patients were randomized (1 : 1) to receive treatment of hypothyroidism with liquid L-T4 or tablet form. The first check-up evaluation was made from 8 to 12 months after 131I remnant ablation. TSH values were established again after further 12 months. Results. A significant increase in TSH values (median) was observed in patients taking tablets [TSH (min–max): 0.28 (0.1–0.45) versus 0.34 (0.01–0.78) mIU/L, p=0.041] as compared to those taking liquid formulation [TSH (min–max): 0.28 (0.1–0.47) versus 0.30 (0.1–0.55) mIU/L, p=0.345]. Conclusions. The use of L-T4 liquid formulation, as compared to that of tablets, resulted in a significantly higher number of DTC patients maintaining TSH values in range for the ATA risk score, reducing TSH variability over the time.

Sign in / Sign up

Export Citation Format

Share Document